Press release
Mar 23, 2023

Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting

 ・Eiko Tomita, Vice President, Global Regulatory Affairs at Bristol Myers Squibb, elected to the Company’s Board of Directors

 ・Candelle Chong promoted to Executive Vice President and Chief of Staff, previously Senior Vice President, Corporate Strategy


Tokyo, Japan and Cambridge, UK, 23 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, announces the election of Ms. Eiko Tomita to the Board of Directors as an Independent External Director, and the promotion of Ms. Candelle Chong to Executive Vice President and Chief of Staff at the Company’s 33rd Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held today in Tokyo. 

Shinichi Tamura, Chairman of Sosei Heptares, said: “I am thrilled to welcome Eiko to the Board of Directors at Sosei Heptares. She is a highly experienced pharmaceutical executive, and her deep knowledge of drug development, regulatory affairs and product commercialization, both internationally and in Japan, will be a significant addition as the Company drives its core strategy towards becoming one of Japan’s biopharmaceutical champions.”

Chris Cargill, President & CEO of Sosei Heptares, added: “I would like to congratulate Candelle on her well-deserved promotion. This newly created role is key to the successful management and growth of Sosei Heptares and will benefit from Candelle’s proven track record in strategy implementation and operations across multiple areas such as business development, corporate finance transactions, communications, investor relations and human resources.” 



Ms. Eiko Tomita

Eiko has over 35 years’ experience in the pharmaceutical industry, both internationally and in Japan, having held roles across R&D, business strategy and commercialization at several global biopharmaceutical companies. Eiko currently serves as Vice President, Global Regulatory Affairs at Bristol Myers Squibb where she oversees regulatory affairs in over 40 countries. Prior to joining Bristol Myers Squibb in 2007, Eiko held roles at Pfizer, AstraZeneca, Monsanto and Eisai. 

Eiko is a qualified pharmacist and holds an MBA from the University of Wales, Cardiff. 

Ms. Candelle Chong

Candelle joined Sosei Heptares in April 2018 as Vice President Corporate Strategy and was promoted to Executive Vice President and Chief of Staff in March 2023. Candelle has also held interim positions as Head of Human Resources and Head of Site Operations and has managed group strategic projects, corporate finance transactions, internal and external communications and investor relations. 

Prior to joining Sosei Heptares, Candelle spent over five years in healthcare investment banking at J.P. Morgan in Sydney, Australia and in London, UK. She holds a Bachelor of Laws (Hons.) and a Bachelor of Commerce (Finance) from the University of New South Wales, Australia.


Further details of the Board of Directors and Executive Officers 


Board of Directors (effective 23 March 2023)

  • Chairman of the Board                                                                      Shinichi Tamura (reappointed)
  • Representative Executive Officer                                                      Chris Cargill (reappointed)
  • Independent External Director                                                           Tomohiro Tohyama (reappointed)
  • Independent External Director                                                           Kuniaki Kaga (reappointed)
  • Independent External Director                                                           David Roblin (reappointed)
  • Independent External Director                                                           Noriaki Nagai (reappointed)
  • Independent External Director                                                           Rolf Soderstrom (reappointed)
  • Independent External Director                                                           Miwa Seki (reappointed)
  • Independent External Director                                                           Eiko Tomita (appointed)                                              

Executive Officers (effective 23 March 2023)

  • President & Chief Executive Officer                                                          Chris Cargill
  • EVP, President of Heptares Therapeutics, Head of UK R&D                    Matt Barnes 
  • EVP, Chief Financial Officer                                                                       Hironoshin Nomura
  • EVP, Chief Accounting Officer                                                                    Kieran Johnson
  • EVP, Chief Compliance Officer                                                                   Kazuhiko Yoshizumi
  • EVP, Chief of Staff                                                                                     Candelle Chong